Akari Therapeutics Plc AKTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-19.86
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$17.3M | — | — | $28.3M |
| 2024 | — | -$19.8M | — | — | $22.2M |
| 2023 | — | -$10.0M | — | — | -$229,000 |
| 2022 | — | -$17.7M | — | — | $1.8M |
| 2021 | — | -$17.4M | — | — | $5.6M |
| 2020 | — | -$17.1M | — | — | $9.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Farag Kameel D. | Interim CFO | 2026-06-24 | Grant | 1,248 | $10.02 |
| Farag Kameel D. | Interim CFO | 2026-06-24 | Grant | 1,395 | $9.32 |
| Farag Kameel D. | Interim CFO | 2026-06-24 | Grant | 1,570 | $8.28 |
| Farag Kameel D. | Interim CFO | 2026-06-24 | Grant | 2,539 | $5.12 |
| Farag Kameel D. | Interim CFO | 2026-06-24 | Grant | 3,725 | $3.49 |
| Farag Kameel D. | Interim CFO | 2026-06-24 | Grant | 7,353 | $3.74 |
| Farag Kameel D. | Interim CFO | 2026-06-24 | Grant | 1,000 | $13.00 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -19.86 (distress)
- Working capital / assets -0.144
- Retained earnings / assets -5.524
- EBIT / assets -0.361
- Equity / liabilities 1.448
Source: SEC EDGAR filings · CIK 0001541157 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.